Medicare AdvantageCoverageMedium impact
MA08.178, Crovalimab-akkz (PiaSky)
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.178 for Crovalimab-akkz (PiaSky), a pharmacy-related drug policy, has been reissued and will take effect on May 28, 2025. This is a very recent policy update that requires immediate attention from billing teams to ensure proper coverage and billing procedures are in place.
Action Required
Before May 28, 2025: Billing team must review the full MA08.178 policy document at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing guidelines for Crovalimab-akkz (PiaSky). Update pharmacy benefit protocols and staff training accordingly. Coordinate with providers who may prescribe this medication to ensure compliance with new policy requirements.